

Genomtec S.A. has launched a review of strategic options and signed an agreement to evaluate the company's IP portfolio

Genomtec S.A., a medical technology Company specializing in the development of advanced genetic diagnostic tools, has decided to initiate a review of strategic options. In addition, it has signed an agreement with Dennemeyer & Associates, a global patent law firm to perform an assessment of the value of the Company's Intellectual Property (IP) portfolio.

As part of the review of strategic options, Genomtec's Management Board may consider, amongst other options: changing the ownership structure, entering into an alliance or strategic partnership, merging with another entity, including, if necessary as seeking an investor for the Company, including an industry investor or financial investor. At present, the Management Board has not made any decisions regarding the selection of any specific option, and the review of options itself may be a lengthy process and does not guarantee any outcome.

- We are constantly pursuing Genomtec's long-term growth strategy. Our Genomtec® ID Respiratory Panel 5-PLEX diagnostic test for simultaneous identification of five pathogens is already CE-IVD marked for sale in 30 European countries. We have also signed the first distribution agreements for our solution. We will continue to expand our distributor base and manufacturing capacity. We believe these activities will have a positive impact on the pursuit of our main business goal, which is to license or sell the technology to a global strategic partner – **said Miron Tokarski, Chief Executive Officer and co-founder of Genomtec S.A.**

As a first step to facilitate the Board of Directors' full analysis of possible strategic options, the Company entered into an agreement with Dennemeyer Consulting GmbH, which will conduct a valuation of the intellectual property portfolio held by the Company. Dennemeyer is a well-recognized global firm that provides legal services for patents, trademarks, data verification and other services related to intellectual property portfolio management.

- *Later this year, we plan to start cooperation with a professional advisory firm specializing in M&A transactions. We know that concluding a strategic partnership is a complex process, so we want to prepare for it properly* – **said Charudutt Shah, Chief Business Officer at Genomtec S.A.**

The Genomtec® ID RP5-PLEX diagnostic panel, simultaneously detects the presence of five pathogens for respiratory infections: Influenza A/B virus, RSV (Respiratory Syncytial Virus), SARS-CoV-2, and the atypical bacteria: Mycoplasma pneumoniae and Chlamydia pneumoniae. The Genomtec® ID Analyzer, which works with the RP5-PLEX microfluidic reaction card (panel), is one of the smallest portable genetic analyzers in the world.

About Genomtec:

Genomtec is a MedTech company specializing in developing advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows fast and precise molecular analysis outside the laboratory environment without the need for skilled laboratory personnel. The solution uses microfluidic technology and proprietary, patent-protected SNAAT isothermal technology.

The company has CE-IVD certification for the Genomtec ID RP5- PLEX diagnostic panel, simultaneously detects the presence of five pathogens for respiratory infections: influenza viruses, RSV (Respiratory Syncytial Virus), SARS-CoV-2, and the atypical bacteria: mycoplasma pneumoniae and chlamydia pneumoniae.

The company is headquartered in Wroclaw, Poland. Genomtec also has a branch in the UK, where part of the international research and engineering team is located.

More information: www.genomtec.com

Contact for media:

Kamil Majcher

NewTech Comm

k.majcher@newtechcomm.pl

+48 507 649 596